Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
about
Pharmacotherapy for uveitis: current management and emerging therapy.Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study.Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.Optical coherence tomography imaging in uveitis.New pharmacotherapy options for noninfectious posterior uveitis.Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis.
P2860
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
@ast
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
@en
type
label
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
@ast
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
@en
prefLabel
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
@ast
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
@en
P2093
P2860
P356
P1476
Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.
@en
P2093
Keith J Wroblewski
Lisa J Faia
Steven Yeh
Zhuqing Li
P2860
P304
P356
10.1167/IOVS.10-5896
P407
P577
2011-08-01T00:00:00Z